Search
Casirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigational[L39130,L39135] Full safety and efficacy data are not yet available, and further evaluation of this investigational therapy will continue.[L23539,L23529,L14303]
Abametapir
go.drugbank.com/drugs/DB11932Approved[A216178] Abemetapir is an inhibitor of these metalloproteinase enzymes, and the first topical pediculicide to take advantage of this novel target. … pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following the first to kill
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsApixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Ag-apixaban, Mar-apixabanGlutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITOMegestrol acetate Action Pathway
smpdb.ca/view/SMP0126528Drug actionMegestrol acetate is a synthetic progestational hormone initially developed as a contraceptive. Nowadays, it is used as a drug to treat anorexia and cachexia (or unexplained weight loss) and as an antineoplastic agent to treat inoperable...
Enzymes: Estradiol 17-beta-dehydrogenase 1Norelgestromin Action Pathway
smpdb.ca/view/SMP0126539Drug actionThis drug is also available in combination with ethinyl estradiol as a vaginal ring.
Enzymes: Estradiol 17-beta-dehydrogenase 1Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … [A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse
Mixtures: PB Hyos, Re-PB HyosCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCupric sulfate
go.drugbank.com/drugs/DB06778ApprovedThe average daily intake of copper in the USA is approximately 1 mg Cu with the diet being a primary source [A32221]. … Copper is an essential trace element and an important catalyst for heme synthesis and iron absorption. After zinc and iron, copper is the third most abundant trace element found in the human body.
Mixtures: Se-Tan PLUS, Pnv-VP-UProducts: Micro CuOsilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigational[L53348][L53353] Linvoseltamab is indicated for adult patients with RRMM who have previously received at least three classes of therapy: a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 … By binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity.